Find Clinical Trial
An International Phase Ib Multicentre Study to Characterize the Safety and Tolerability of Intravenously Administered S64315 a Selective Mcl-1 Inhibitor, in Combination With Orally Administered Venetoclax a Selective Bcl-2 Inhibitor in Patients With Acute Myeloid Leukaemia
← Back
| Study Phase |
Phase 1 |
| Therapeutic Area |
Cancers |
| Indication | Blood cancer |
| Sponsor | Institut de Recherches Internationales Servier (I.R.I.S) |
| Active substance/ Medical device |
S064315 |
| Active Substance Code | S064315 |
| Protocol Code | CL1-64315-002 |
| EudraCT Code | 2018-001809-88 |
| NCT Code | NCT03672695 |
Documents and links
| Lay summary | |
| Results summary | READ MORE  |
Servier Glossary of Terms
To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.
© 2024 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility
